AU2007245169B2 - Reagents and methods for cancer treatment and prevention - Google Patents
Reagents and methods for cancer treatment and prevention Download PDFInfo
- Publication number
- AU2007245169B2 AU2007245169B2 AU2007245169A AU2007245169A AU2007245169B2 AU 2007245169 B2 AU2007245169 B2 AU 2007245169B2 AU 2007245169 A AU2007245169 A AU 2007245169A AU 2007245169 A AU2007245169 A AU 2007245169A AU 2007245169 B2 AU2007245169 B2 AU 2007245169B2
- Authority
- AU
- Australia
- Prior art keywords
- cells
- thapsigargin
- cancer cells
- cancer
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/902—Oxidoreductases (1.)
- G01N2333/90241—Oxidoreductases (1.) acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/389,695 | 2006-03-27 | ||
| US11/389,695 US9107863B2 (en) | 2006-03-27 | 2006-03-27 | Reagents and methods for cancer treatment and prevention |
| PCT/US2007/007526 WO2007126787A2 (en) | 2006-03-27 | 2007-03-27 | Reagents and methods for cancer treatment and prevention |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2007245169A1 AU2007245169A1 (en) | 2007-11-08 |
| AU2007245169B2 true AU2007245169B2 (en) | 2012-05-24 |
Family
ID=38533710
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2007245169A Ceased AU2007245169B2 (en) | 2006-03-27 | 2007-03-27 | Reagents and methods for cancer treatment and prevention |
Country Status (8)
| Country | Link |
|---|---|
| US (4) | US9107863B2 (cg-RX-API-DMAC10.html) |
| EP (2) | EP2004219B1 (cg-RX-API-DMAC10.html) |
| JP (2) | JP5422377B2 (cg-RX-API-DMAC10.html) |
| CN (1) | CN101443036A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2007245169B2 (cg-RX-API-DMAC10.html) |
| CA (1) | CA2647542A1 (cg-RX-API-DMAC10.html) |
| ES (2) | ES2548435T3 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2007126787A2 (cg-RX-API-DMAC10.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3376495B2 (ja) | 1992-08-18 | 2003-02-10 | ソニー株式会社 | 接着剤の塗布方法及び接着治具 |
| US9107863B2 (en) | 2006-03-27 | 2015-08-18 | The Buck Institute For Age Reasearch | Reagents and methods for cancer treatment and prevention |
| CZ300806B6 (cs) * | 2007-07-18 | 2009-08-12 | Ústav experimentální mediciny AV CR, v.v.i. | Imunostimulacní úcinky trilobolidu a zpusob jeho prípravy |
| US9446141B2 (en) * | 2013-03-15 | 2016-09-20 | Genspera, Inc. | Methods of producing cancer compounds |
| EP2796137A1 (en) * | 2013-04-22 | 2014-10-29 | Universität des Saarlandes | SERCA inhibitor and Calmodulin antagonist combination |
| CN112891354B (zh) * | 2021-03-18 | 2022-10-21 | 新乡医学院 | MDM2抑制剂Nutlin-3a在制备激活内质网应激诱导的癌细胞凋亡药物中的应用 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004037321A2 (en) * | 2002-10-25 | 2004-05-06 | University Of Connecticut Health Center | Immunotherapy of cancer through controlled cell lysis |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4671958A (en) | 1982-03-09 | 1987-06-09 | Cytogen Corporation | Antibody conjugates for the delivery of compounds to target sites |
| US4867973A (en) | 1984-08-31 | 1989-09-19 | Cytogen Corporation | Antibody-therapeutic agent conjugates |
| IN165717B (cg-RX-API-DMAC10.html) | 1986-08-07 | 1989-12-23 | Battelle Memorial Institute | |
| US5904920A (en) | 1991-10-04 | 1999-05-18 | Whitehead Institute For Biomedical Research | Regulation of systemic immune responses utilizing cytokines and antigens |
| US5637483A (en) | 1991-10-04 | 1997-06-10 | Whitehead Institute For Biomedical Research | Irradiated tumor cell vaccine engineered to express GM-CSF |
| US20010033839A1 (en) * | 1999-10-04 | 2001-10-25 | Emilio Barbera-Guillem | Vaccine and immunotherapy for solid nonlymphoid tumor and related immune dysregulation |
| AU5458500A (en) | 1999-06-02 | 2000-12-18 | Cell Genesys, Inc. | Regulation of systemic immune responses utilizing cytokines and antigens |
| JP2001010973A (ja) * | 1999-06-29 | 2001-01-16 | Dnavec Research Inc | がんワクチン |
| WO2001022972A2 (en) * | 1999-09-25 | 2001-04-05 | University Of Iowa Research Foundation | Immunostimulatory nucleic acids |
| US7056491B2 (en) * | 2000-11-08 | 2006-06-06 | Wisconsin Alumni Research Foundation | Monoterpenes and sesquiterpenes as chemotherapeutic and radiation sensitizers and immunomodulators |
| CA2356438A1 (en) * | 2001-09-05 | 2003-03-05 | Andre Pichette | Use of terpenes and derivatives as potentiators of antitumor agents in the treatment of cancers |
| US7402406B2 (en) * | 2001-10-31 | 2008-07-22 | Astellas Pharma Inc. | Methods of evaluating phosphatase inhibitors |
| WO2003087129A2 (en) * | 2002-04-08 | 2003-10-23 | Siga Technologies, Inc. | Immunogenic peptides, and method of identifying same |
| WO2005051423A2 (en) * | 2003-11-30 | 2005-06-09 | Yeda Research And Development Co. Ltd | Methods and agents for immune modulation and methods for identifying immune modulators |
| US9107863B2 (en) * | 2006-03-27 | 2015-08-18 | The Buck Institute For Age Reasearch | Reagents and methods for cancer treatment and prevention |
-
2006
- 2006-03-27 US US11/389,695 patent/US9107863B2/en not_active Expired - Fee Related
-
2007
- 2007-03-27 AU AU2007245169A patent/AU2007245169B2/en not_active Ceased
- 2007-03-27 WO PCT/US2007/007526 patent/WO2007126787A2/en not_active Ceased
- 2007-03-27 EP EP07754097.9A patent/EP2004219B1/en not_active Not-in-force
- 2007-03-27 JP JP2009502932A patent/JP5422377B2/ja not_active Expired - Fee Related
- 2007-03-27 ES ES07754097.9T patent/ES2548435T3/es active Active
- 2007-03-27 ES ES15180408.5T patent/ES2655909T3/es active Active
- 2007-03-27 CA CA002647542A patent/CA2647542A1/en not_active Abandoned
- 2007-03-27 CN CNA2007800162837A patent/CN101443036A/zh active Pending
- 2007-03-27 EP EP15180408.5A patent/EP2974738B1/en not_active Not-in-force
-
2010
- 2010-04-29 US US12/770,638 patent/US8895031B2/en active Active
-
2013
- 2013-08-20 JP JP2013170115A patent/JP5712257B2/ja not_active Expired - Fee Related
-
2015
- 2015-07-15 US US14/800,412 patent/US9885704B2/en not_active Expired - Fee Related
-
2017
- 2017-12-22 US US15/852,606 patent/US20180128816A1/en not_active Abandoned
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004037321A2 (en) * | 2002-10-25 | 2004-05-06 | University Of Connecticut Health Center | Immunotherapy of cancer through controlled cell lysis |
Non-Patent Citations (2)
| Title |
|---|
| DENMEADE, S.R. et al. Journal of the National Cancer Institute. 2003. 95(13): 990-1000 * |
| LOWRY, D.T et al. Carcinogenesis, 1996. 17(4): 699-706 * |
Also Published As
| Publication number | Publication date |
|---|---|
| US9885704B2 (en) | 2018-02-06 |
| US8895031B2 (en) | 2014-11-25 |
| EP2004219A4 (en) | 2010-06-30 |
| AU2007245169A1 (en) | 2007-11-08 |
| ES2548435T3 (es) | 2015-10-16 |
| CA2647542A1 (en) | 2007-11-08 |
| WO2007126787A2 (en) | 2007-11-08 |
| US20100278874A1 (en) | 2010-11-04 |
| EP2974738A1 (en) | 2016-01-20 |
| CN101443036A (zh) | 2009-05-27 |
| US20070224207A1 (en) | 2007-09-27 |
| EP2004219A2 (en) | 2008-12-24 |
| EP2004219B1 (en) | 2015-09-16 |
| ES2655909T3 (es) | 2018-02-22 |
| JP5422377B2 (ja) | 2014-02-19 |
| US9107863B2 (en) | 2015-08-18 |
| WO2007126787A3 (en) | 2008-10-23 |
| EP2974738B1 (en) | 2017-11-15 |
| US20180128816A1 (en) | 2018-05-10 |
| JP5712257B2 (ja) | 2015-05-07 |
| US20160069864A1 (en) | 2016-03-10 |
| JP2014028815A (ja) | 2014-02-13 |
| JP2009535298A (ja) | 2009-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20180128816A1 (en) | Reagents and Methods for Cancer Treatment and Prevention | |
| Son et al. | Immunogenic cell death induced by ginsenoside Rg3: significance in dendritic cell-based anti-tumor immunotherapy | |
| AU2010270291B2 (en) | Process for the identification of compounds for treating cancer | |
| Deng et al. | The natural product phyllanthusmin C enhances IFN-γ production by human NK cells through upregulation of TLR-mediated NF-κB signaling | |
| TW201924722A (zh) | 用於刺激第i型干擾素基因之方法及包含陽離子脂質的組合物 | |
| Gu et al. | Gambogic acid induced tumor cell apoptosis by T lymphocyte activation in H22 transplanted mice | |
| Yan et al. | Bryostatin-I: a dendritic cell stimulator for chemokines induction and a promising adjuvant for a peptide based cancer vaccine | |
| Tancharoen et al. | The role of water channel aquaporin 3 in the mechanism of TNF‐α‐mediated proinflammatory events: Implication in periodontal inflammation | |
| Lee et al. | Venlafaxine inhibits the development and differentiation of dendritic cells through the regulation of P-glycoprotein | |
| KR20200120342A (ko) | Il-21을 이용한 항원 특이적 cd8+ t 세포의 증식 촉진 또는 대량 배양 방법 | |
| HK40105290A (en) | Immuno-oncology therapeutic composition using adjuvant including lipopeptides and poly (i:c) | |
| Yamaoka et al. | WS/PP-024b-11 Spatiotemporal regulation of heat shock protein 90-chaperoned self-DNA and CpG-oligodeoxynucleotide for type-I interferon induction via targeting to static early endosome Y. Tamura, K. Saito, K. Okuya, T. Torigoe, N. Sato. Sapporo Medical University School of Medicine, Sapporo, Japan | |
| Molavi | Delivery of STAT3 inhibitor cucurbitacins to tumor by polymeric nano-carriers: Implications in cancer chemo-and immunotherapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |